Review



human tgct embryonal carcinoma ec cell lines nt2 d1  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    ATCC human tgct embryonal carcinoma ec cell lines nt2 d1
    Cisplatin-resistant <t>TGCT</t> cells have a less robust transcriptional response to cisplatin compared to parental cells. ( A ) Volcano plots of the cisplatin response of 2102EP parental and three independently derived cisplatin-resistant cell derivatives. ( B ) Volcano plots of the cisplatin response <t>of</t> <t>NT2/D1</t> parental and two independently derived cisplatin-resistant cell derivatives. ( C ) Volcano plots of the cisplatin response of 833K parental and two independently derived cisplatin-resistant cell derivatives. ( D ) Number of genes upregulated and downregulated (>1.3 fold change and an FDR < 0.01) after cisplatin treatment in indicated parental and resistant cells.
    Human Tgct Embryonal Carcinoma Ec Cell Lines Nt2 D1, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 151 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human tgct embryonal carcinoma ec cell lines nt2 d1/product/ATCC
    Average 95 stars, based on 151 article reviews
    human tgct embryonal carcinoma ec cell lines nt2 d1 - by Bioz Stars, 2026-04
    95/100 stars

    Images

    1) Product Images from "Comparative Analysis of the Transcriptomic Response to Cisplatin in Drug-Sensitive and Drug-Resistant Testicular Germ Cell Tumors"

    Article Title: Comparative Analysis of the Transcriptomic Response to Cisplatin in Drug-Sensitive and Drug-Resistant Testicular Germ Cell Tumors

    Journal: Cancers

    doi: 10.3390/cancers18040575

    Cisplatin-resistant TGCT cells have a less robust transcriptional response to cisplatin compared to parental cells. ( A ) Volcano plots of the cisplatin response of 2102EP parental and three independently derived cisplatin-resistant cell derivatives. ( B ) Volcano plots of the cisplatin response of NT2/D1 parental and two independently derived cisplatin-resistant cell derivatives. ( C ) Volcano plots of the cisplatin response of 833K parental and two independently derived cisplatin-resistant cell derivatives. ( D ) Number of genes upregulated and downregulated (>1.3 fold change and an FDR < 0.01) after cisplatin treatment in indicated parental and resistant cells.
    Figure Legend Snippet: Cisplatin-resistant TGCT cells have a less robust transcriptional response to cisplatin compared to parental cells. ( A ) Volcano plots of the cisplatin response of 2102EP parental and three independently derived cisplatin-resistant cell derivatives. ( B ) Volcano plots of the cisplatin response of NT2/D1 parental and two independently derived cisplatin-resistant cell derivatives. ( C ) Volcano plots of the cisplatin response of 833K parental and two independently derived cisplatin-resistant cell derivatives. ( D ) Number of genes upregulated and downregulated (>1.3 fold change and an FDR < 0.01) after cisplatin treatment in indicated parental and resistant cells.

    Techniques Used: Derivative Assay

    p53/TFRC1/MYC target genes are associated with disease-free survival in TGCT patients. High expression of a partially overlapping subset of genes associated with p53 activation and TFRC1 and MYC repression were associated with increased disease-free survival in TGCT patients as assessed by Kaplan–Meier log-rank tests. HR, hazard ratio; CI, confidence interval.
    Figure Legend Snippet: p53/TFRC1/MYC target genes are associated with disease-free survival in TGCT patients. High expression of a partially overlapping subset of genes associated with p53 activation and TFRC1 and MYC repression were associated with increased disease-free survival in TGCT patients as assessed by Kaplan–Meier log-rank tests. HR, hazard ratio; CI, confidence interval.

    Techniques Used: Expressing, Activation Assay



    Similar Products

    human tgct embryonal carcinoma ec cell lines nt2 d1  (ATCC)
    95
    ATCC human tgct embryonal carcinoma ec cell lines nt2 d1
    Cisplatin-resistant <t>TGCT</t> cells have a less robust transcriptional response to cisplatin compared to parental cells. ( A ) Volcano plots of the cisplatin response of 2102EP parental and three independently derived cisplatin-resistant cell derivatives. ( B ) Volcano plots of the cisplatin response <t>of</t> <t>NT2/D1</t> parental and two independently derived cisplatin-resistant cell derivatives. ( C ) Volcano plots of the cisplatin response of 833K parental and two independently derived cisplatin-resistant cell derivatives. ( D ) Number of genes upregulated and downregulated (>1.3 fold change and an FDR < 0.01) after cisplatin treatment in indicated parental and resistant cells.
    Human Tgct Embryonal Carcinoma Ec Cell Lines Nt2 D1, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human tgct embryonal carcinoma ec cell lines nt2 d1/product/ATCC
    Average 95 stars, based on 1 article reviews
    human tgct embryonal carcinoma ec cell lines nt2 d1 - by Bioz Stars, 2026-04
    95/100 stars
    		  Buy from Supplier
    human endometrial cancer ec cell lines an3ca  (ATCC)
    96
    ATCC human endometrial cancer ec cell lines an3ca
    Cisplatin-resistant <t>TGCT</t> cells have a less robust transcriptional response to cisplatin compared to parental cells. ( A ) Volcano plots of the cisplatin response of 2102EP parental and three independently derived cisplatin-resistant cell derivatives. ( B ) Volcano plots of the cisplatin response <t>of</t> <t>NT2/D1</t> parental and two independently derived cisplatin-resistant cell derivatives. ( C ) Volcano plots of the cisplatin response of 833K parental and two independently derived cisplatin-resistant cell derivatives. ( D ) Number of genes upregulated and downregulated (>1.3 fold change and an FDR < 0.01) after cisplatin treatment in indicated parental and resistant cells.
    Human Endometrial Cancer Ec Cell Lines An3ca, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human endometrial cancer ec cell lines an3ca/product/ATCC
    Average 96 stars, based on 1 article reviews
    human endometrial cancer ec cell lines an3ca - by Bioz Stars, 2026-04
    96/100 stars
    		  Buy from Supplier
    human umbilical vein endothelial cell line huvec  (ATCC)
    96
    ATCC human umbilical vein endothelial cell line huvec
    Cisplatin-resistant <t>TGCT</t> cells have a less robust transcriptional response to cisplatin compared to parental cells. ( A ) Volcano plots of the cisplatin response of 2102EP parental and three independently derived cisplatin-resistant cell derivatives. ( B ) Volcano plots of the cisplatin response <t>of</t> <t>NT2/D1</t> parental and two independently derived cisplatin-resistant cell derivatives. ( C ) Volcano plots of the cisplatin response of 833K parental and two independently derived cisplatin-resistant cell derivatives. ( D ) Number of genes upregulated and downregulated (>1.3 fold change and an FDR < 0.01) after cisplatin treatment in indicated parental and resistant cells.
    Human Umbilical Vein Endothelial Cell Line Huvec, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human umbilical vein endothelial cell line huvec/product/ATCC
    Average 96 stars, based on 1 article reviews
    human umbilical vein endothelial cell line huvec - by Bioz Stars, 2026-04
    96/100 stars
    		  Buy from Supplier
    human umbilical vein endothelial cell lines  (ATCC)
    96
    ATCC human umbilical vein endothelial cell lines
    Cisplatin-resistant <t>TGCT</t> cells have a less robust transcriptional response to cisplatin compared to parental cells. ( A ) Volcano plots of the cisplatin response of 2102EP parental and three independently derived cisplatin-resistant cell derivatives. ( B ) Volcano plots of the cisplatin response <t>of</t> <t>NT2/D1</t> parental and two independently derived cisplatin-resistant cell derivatives. ( C ) Volcano plots of the cisplatin response of 833K parental and two independently derived cisplatin-resistant cell derivatives. ( D ) Number of genes upregulated and downregulated (>1.3 fold change and an FDR < 0.01) after cisplatin treatment in indicated parental and resistant cells.
    Human Umbilical Vein Endothelial Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human umbilical vein endothelial cell lines/product/ATCC
    Average 96 stars, based on 1 article reviews
    human umbilical vein endothelial cell lines - by Bioz Stars, 2026-04
    96/100 stars
    		  Buy from Supplier
    human ec cell lines  (ATCC)
    96
    ATCC human ec cell lines
    ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) correlates with vascular endothelial growth factor‐A (VEGF‐A) expression in endometrial cancer (EC). (a) The Cancer Genome Atlas (TCGA)‐based correlation analysis of ST3Gal1 mRNA expression with key genes involved in angiogenesis and metastasis, including VEGF, TGF‐β1, VEGFR2, HIF‐1α, and endothelial growth factor (EGF). (b) Comparative correlation of ST3Gal1 with VEGF‐A, VEGF‐B, and VEGF‐C, highlighting the strongest association with VEGF‐A. (c, d) mRNA expression levels of ST3Gal1 (c) and VEGF‐A (d) in <t>EC</t> <t>cell</t> lines (HEC‐1A, HEC‐1B, RL95‐2, HEC‐50B), with significant upregulation observed in RL95‐2 and HEC‐1B. (e) Western blot analysis of ST3Gal1 and VEGF‐A protein expression across four EC cell lines.
    Human Ec Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human ec cell lines/product/ATCC
    Average 96 stars, based on 1 article reviews
    human ec cell lines - by Bioz Stars, 2026-04
    96/100 stars
    		  Buy from Supplier
    human ec cell lines hec1b  (China Center for Type Culture Collection)
    90
    China Center for Type Culture Collection human ec cell lines hec1b
    ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) correlates with vascular endothelial growth factor‐A (VEGF‐A) expression in endometrial cancer (EC). (a) The Cancer Genome Atlas (TCGA)‐based correlation analysis of ST3Gal1 mRNA expression with key genes involved in angiogenesis and metastasis, including VEGF, TGF‐β1, VEGFR2, HIF‐1α, and endothelial growth factor (EGF). (b) Comparative correlation of ST3Gal1 with VEGF‐A, VEGF‐B, and VEGF‐C, highlighting the strongest association with VEGF‐A. (c, d) mRNA expression levels of ST3Gal1 (c) and VEGF‐A (d) in <t>EC</t> <t>cell</t> lines (HEC‐1A, HEC‐1B, RL95‐2, HEC‐50B), with significant upregulation observed in RL95‐2 and HEC‐1B. (e) Western blot analysis of ST3Gal1 and VEGF‐A protein expression across four EC cell lines.
    Human Ec Cell Lines Hec1b, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human ec cell lines hec1b/product/China Center for Type Culture Collection
    Average 90 stars, based on 1 article reviews
    human ec cell lines hec1b - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    human endothelial cell ec line ea hy926  (ATCC)
    97
    ATCC human endothelial cell ec line ea hy926
    ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) correlates with vascular endothelial growth factor‐A (VEGF‐A) expression in endometrial cancer (EC). (a) The Cancer Genome Atlas (TCGA)‐based correlation analysis of ST3Gal1 mRNA expression with key genes involved in angiogenesis and metastasis, including VEGF, TGF‐β1, VEGFR2, HIF‐1α, and endothelial growth factor (EGF). (b) Comparative correlation of ST3Gal1 with VEGF‐A, VEGF‐B, and VEGF‐C, highlighting the strongest association with VEGF‐A. (c, d) mRNA expression levels of ST3Gal1 (c) and VEGF‐A (d) in <t>EC</t> <t>cell</t> lines (HEC‐1A, HEC‐1B, RL95‐2, HEC‐50B), with significant upregulation observed in RL95‐2 and HEC‐1B. (e) Western blot analysis of ST3Gal1 and VEGF‐A protein expression across four EC cell lines.
    Human Endothelial Cell Ec Line Ea Hy926, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human endothelial cell ec line ea hy926/product/ATCC
    Average 97 stars, based on 1 article reviews
    human endothelial cell ec line ea hy926 - by Bioz Stars, 2026-04
    97/100 stars
    		  Buy from Supplier
    human ec cell lines ce48t/vgh  (BioResource International Inc)
    90
    BioResource International Inc human ec cell lines ce48t/vgh
    ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) correlates with vascular endothelial growth factor‐A (VEGF‐A) expression in endometrial cancer (EC). (a) The Cancer Genome Atlas (TCGA)‐based correlation analysis of ST3Gal1 mRNA expression with key genes involved in angiogenesis and metastasis, including VEGF, TGF‐β1, VEGFR2, HIF‐1α, and endothelial growth factor (EGF). (b) Comparative correlation of ST3Gal1 with VEGF‐A, VEGF‐B, and VEGF‐C, highlighting the strongest association with VEGF‐A. (c, d) mRNA expression levels of ST3Gal1 (c) and VEGF‐A (d) in <t>EC</t> <t>cell</t> lines (HEC‐1A, HEC‐1B, RL95‐2, HEC‐50B), with significant upregulation observed in RL95‐2 and HEC‐1B. (e) Western blot analysis of ST3Gal1 and VEGF‐A protein expression across four EC cell lines.
    Human Ec Cell Lines Ce48t/Vgh, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human ec cell lines ce48t/vgh/product/BioResource International Inc
    Average 90 stars, based on 1 article reviews
    human ec cell lines ce48t/vgh - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Cisplatin-resistant TGCT cells have a less robust transcriptional response to cisplatin compared to parental cells. ( A ) Volcano plots of the cisplatin response of 2102EP parental and three independently derived cisplatin-resistant cell derivatives. ( B ) Volcano plots of the cisplatin response of NT2/D1 parental and two independently derived cisplatin-resistant cell derivatives. ( C ) Volcano plots of the cisplatin response of 833K parental and two independently derived cisplatin-resistant cell derivatives. ( D ) Number of genes upregulated and downregulated (>1.3 fold change and an FDR < 0.01) after cisplatin treatment in indicated parental and resistant cells.

    Journal: Cancers

    Article Title: Comparative Analysis of the Transcriptomic Response to Cisplatin in Drug-Sensitive and Drug-Resistant Testicular Germ Cell Tumors

    doi: 10.3390/cancers18040575

    Figure Lengend Snippet: Cisplatin-resistant TGCT cells have a less robust transcriptional response to cisplatin compared to parental cells. ( A ) Volcano plots of the cisplatin response of 2102EP parental and three independently derived cisplatin-resistant cell derivatives. ( B ) Volcano plots of the cisplatin response of NT2/D1 parental and two independently derived cisplatin-resistant cell derivatives. ( C ) Volcano plots of the cisplatin response of 833K parental and two independently derived cisplatin-resistant cell derivatives. ( D ) Number of genes upregulated and downregulated (>1.3 fold change and an FDR < 0.01) after cisplatin treatment in indicated parental and resistant cells.

    Article Snippet: The human TGCT embryonal carcinoma (EC) cell lines NT2/D1, 833K, and 2102EP were obtained from ATCC.

    Techniques: Derivative Assay

    p53/TFRC1/MYC target genes are associated with disease-free survival in TGCT patients. High expression of a partially overlapping subset of genes associated with p53 activation and TFRC1 and MYC repression were associated with increased disease-free survival in TGCT patients as assessed by Kaplan–Meier log-rank tests. HR, hazard ratio; CI, confidence interval.

    Journal: Cancers

    Article Title: Comparative Analysis of the Transcriptomic Response to Cisplatin in Drug-Sensitive and Drug-Resistant Testicular Germ Cell Tumors

    doi: 10.3390/cancers18040575

    Figure Lengend Snippet: p53/TFRC1/MYC target genes are associated with disease-free survival in TGCT patients. High expression of a partially overlapping subset of genes associated with p53 activation and TFRC1 and MYC repression were associated with increased disease-free survival in TGCT patients as assessed by Kaplan–Meier log-rank tests. HR, hazard ratio; CI, confidence interval.

    Article Snippet: The human TGCT embryonal carcinoma (EC) cell lines NT2/D1, 833K, and 2102EP were obtained from ATCC.

    Techniques: Expressing, Activation Assay

    ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) correlates with vascular endothelial growth factor‐A (VEGF‐A) expression in endometrial cancer (EC). (a) The Cancer Genome Atlas (TCGA)‐based correlation analysis of ST3Gal1 mRNA expression with key genes involved in angiogenesis and metastasis, including VEGF, TGF‐β1, VEGFR2, HIF‐1α, and endothelial growth factor (EGF). (b) Comparative correlation of ST3Gal1 with VEGF‐A, VEGF‐B, and VEGF‐C, highlighting the strongest association with VEGF‐A. (c, d) mRNA expression levels of ST3Gal1 (c) and VEGF‐A (d) in EC cell lines (HEC‐1A, HEC‐1B, RL95‐2, HEC‐50B), with significant upregulation observed in RL95‐2 and HEC‐1B. (e) Western blot analysis of ST3Gal1 and VEGF‐A protein expression across four EC cell lines.

    Journal: International Journal of Gynaecology and Obstetrics

    Article Title: Targeting the ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 ( ST3Gal1 ) as a potential therapeutic strategy to overcome anti‐ VEGF resistance in endometrial cancer

    doi: 10.1002/ijgo.70292

    Figure Lengend Snippet: ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) correlates with vascular endothelial growth factor‐A (VEGF‐A) expression in endometrial cancer (EC). (a) The Cancer Genome Atlas (TCGA)‐based correlation analysis of ST3Gal1 mRNA expression with key genes involved in angiogenesis and metastasis, including VEGF, TGF‐β1, VEGFR2, HIF‐1α, and endothelial growth factor (EGF). (b) Comparative correlation of ST3Gal1 with VEGF‐A, VEGF‐B, and VEGF‐C, highlighting the strongest association with VEGF‐A. (c, d) mRNA expression levels of ST3Gal1 (c) and VEGF‐A (d) in EC cell lines (HEC‐1A, HEC‐1B, RL95‐2, HEC‐50B), with significant upregulation observed in RL95‐2 and HEC‐1B. (e) Western blot analysis of ST3Gal1 and VEGF‐A protein expression across four EC cell lines.

    Article Snippet: Four human EC cell lines—HEC‐1A, HEC‐1B, RL95‐2, and HEC‐50B—were obtained from the American Type Culture Collection (ATCC).

    Techniques: Expressing, Western Blot